Back to articles

Breast cancer drug effective for gastric cancer


Results from a Phase III trial involving almost 600 patients showed that treatment with trastuzumab (Herceptin—Genentech) given in combination with chemotherapy resulted in a 26% reduction in the rate of death for patients with human epidermal growth factor receptor 2 (HER2)–positive advanced gastric or gastroesophageal junction cancer compared with chemotherapy alone.